CA2689293A1 - Prostaglandin prodrugs - Google Patents

Prostaglandin prodrugs Download PDF

Info

Publication number
CA2689293A1
CA2689293A1 CA002689293A CA2689293A CA2689293A1 CA 2689293 A1 CA2689293 A1 CA 2689293A1 CA 002689293 A CA002689293 A CA 002689293A CA 2689293 A CA2689293 A CA 2689293A CA 2689293 A1 CA2689293 A1 CA 2689293A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
formula
chf
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002689293A
Other languages
English (en)
French (fr)
Inventor
David W. Old
Wha Bin Im
Vinh X. Ngo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2689293A1 publication Critical patent/CA2689293A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002689293A 2006-11-17 2007-11-14 Prostaglandin prodrugs Abandoned CA2689293A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86625006P 2006-11-17 2006-11-17
US60/866,250 2006-11-17
PCT/US2007/084684 WO2008064039A2 (en) 2006-11-17 2007-11-14 Prostaglandin prodrugs as ocular hypotensive agents

Publications (1)

Publication Number Publication Date
CA2689293A1 true CA2689293A1 (en) 2008-05-29

Family

ID=39276861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002689293A Abandoned CA2689293A1 (en) 2006-11-17 2007-11-14 Prostaglandin prodrugs

Country Status (6)

Country Link
US (1) US7507817B2 (enExample)
EP (1) EP2094678B1 (enExample)
JP (1) JP5384358B2 (enExample)
BR (1) BRPI0719061A2 (enExample)
CA (1) CA2689293A1 (enExample)
WO (1) WO2008064039A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5532302B2 (ja) * 2006-07-10 2014-06-25 アラーガン インコーポレイテッド 治療化合物
AU2008207991B9 (en) * 2007-01-22 2014-02-27 Allergan, Inc. Thiophene derivatives useful as ocular hypotensive agents
US7960379B2 (en) 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
AU2009239377B2 (en) * 2008-04-24 2014-05-01 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
CN102076681A (zh) 2008-04-24 2011-05-25 阿勒根公司 作为治疗剂的取代γ-内酰胺
ATE550328T1 (de) * 2008-04-24 2012-04-15 Allergan Inc Thiophenderivate, die sich als den augeninnendruck senkende mittel eignen
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
US7981887B2 (en) 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
EP2303836A1 (en) 2008-05-09 2011-04-06 Allergan, Inc. Therapeutic cyclopentane derivatives
AU2009251474B2 (en) * 2008-05-15 2014-06-05 Allergan, Inc. Prostaglandin prodrugs as hypotensive agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH656877A5 (de) * 1981-11-27 1986-07-31 Erba Farmitalia Optisch aktive oder racemische prostaglandinderivate.
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
NZ555945A (en) 2005-01-14 2011-01-28 Allergan Inc Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions

Also Published As

Publication number Publication date
EP2094678B1 (en) 2014-06-04
WO2008064039A3 (en) 2008-07-10
WO2008064039A2 (en) 2008-05-29
AU2007323857A1 (en) 2008-05-29
JP2010510232A (ja) 2010-04-02
BRPI0719061A2 (pt) 2013-11-26
US20080167311A1 (en) 2008-07-10
EP2094678A2 (en) 2009-09-02
JP5384358B2 (ja) 2014-01-08
US7507817B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
EP2094678B1 (en) Prostaglandin prodrugs as ocular hypotensive agents
CA2787914C (en) Therapeutic agents for treatment of ocular hypertension
US8168680B2 (en) Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU2009225693B2 (en) Therapeutic compounds
AU2006244583B2 (en) Substituted beta-lactams and their use in medicine
AU2009239381A1 (en) Substituted gamma lactams as therapeutic agents
WO2007005176A1 (en) Pyrrolidinones for the treatment of glaucoma and ocular hypertension
AU2007323857B2 (en) Prostaglandin prodrugs as ocular hypotensive agents
WO2009111417A1 (en) Substituted beta-lactams
CA2724972A1 (en) Therapeutic compounds
US8263593B2 (en) Therapeutic compounds
US7964634B2 (en) Therapeutic compounds
US20090233921A1 (en) Therapeutic cyclopentane derivatives
US20090239867A1 (en) Therapeutic substituted gamma lactams
CA2787946A1 (en) Therapeutically active cyclopentanes
HK1178524A (en) Therapeutic agents for treatment of ocular hypertension
HK1178524B (en) Therapeutic agents for treatment of ocular hypertension
CA2728227A1 (en) Therapeutic cyclopentane derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160324